Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
2017年1月30日 - 11:00PM
Marketwired
Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market
Closing Bell to Kick-off Lactose Intolerance Awareness Month
LOS ANGELES, CA-(Marketwired - Jan 30, 2017) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a developer of novel therapeutic products that
modulate the human gut microbiome to treat gastrointestinal
diseases, will be ringing the closing bell for the Nasdaq stock
market in New York today, Monday, January 30, 2017 at 4:00 p.m. EST
to kick-off Lactose Intolerance Awareness Month.
Ira E. Ritter, Co-founder and Chairman of Ritter
Pharmaceuticals' Board of Directors, commented, "Its important to
make people aware that lactose intolerance dramatically affects
over 40 million people in the U.S. of which 9 million suffer
moderate to severe symptoms. Lactose Intolerance is a condition
with few treatment options where over 50% of sufferers report their
intolerance moderately or severely impacts their daily
activities.(1) There is a huge unmet medical need here and we have
dedicated our last 13 years to pursuing the development of a better
treatment option."
Ritter Pharmaceuticals' lead product candidate, RP-G28, has the
potential to become the first FDA-approved treatment for lactose
intolerance. RP-G28 was recently studied in a 377-subject Phase
2b/3 clinical trial, with data readout expected this quarter.
"The Company has had a busy start to 2017," said Michael Step,
Chief Executive Officer of Ritter Pharmaceuticals "We announced the
publication of our Phase 2a study's microbiome data in the
prestigious peer-reviewed journal Proceedings of the National
Academy of Sciences, established a collaboration with the
University of Nebraska to study the role of the microbiome and
RP-G28 in metabolic syndrome, and appointed William Merino, Ph.D.,
a former Senior Vice President of Worldwide Regulatory Affairs at
Warner Lambert Pharmaceuticals, to our Board of Directors."
Chairman, Co-Founder and Chief Strategic Officer Ira E. Ritter
ringing the Nasdaq bell can be viewed live today, Monday, January
30, 2017 at 4:00 p.m. EST via a live webcast:
https://new.livestream.com/nasdaq/live
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products
that modulate the gut microbiome to treat gastrointestinal
diseases. Its lead product, RP-G28, has the potential to become the
first FDA-approved treatment for lactose intolerance, a condition
that affects millions worldwide. The company is further exploring
functionality and discovering therapeutic potential gut microbiome
changes may have on treating/preventing a variety of areas
including: gastrointestinal diseases, immune-oncology, metabolic,
and liver disease. For additional information, go to
www.RitterPharma.com and follow the Company at @RitterPharma.
Forward-Looking Statements
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements related to the release of results from the
Company's Phase 2b/3 clinical trial of RP-G28. Management believes
that these forward-looking statements are reasonable as and when
made. However, such statements involve a number of known and
unknown risks and uncertainties that could cause the Company's
future results, performance or achievements to differ significantly
from the results, performance or achievements expressed or implied
by such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the drug
development process generally, including the outcomes of planned
clinical trials and the regulatory review process. For a discussion
of certain risks and uncertainties affecting Ritter
Pharmaceuticals' forward-looking statements, please review the
Company's reports filed with the Securities and Exchange
Commission, including, but not limited to, its Annual Report on
Form 10-K for the period ended December 31, 2015 and Quarterly
Reports on Form 10-Q for the periods ended March 31, 2016, June 30,
2016 and September 30, 2016. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date on which they are made. These statements are
based on management's current expectations and Ritter
Pharmaceuticals does not undertake any responsibility to revise or
update any forward-looking statements contained herein, except as
expressly required by law.
(1) Objective Insights, "Market Research Analysis and Forecasts
on Lactose Intolerance and RP-G28." June, 2012.
Contact Information
Contacts Ellen Mochizuki 310-203-1000 ellen@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024